Myriad Genetics (MYGN) News Today $12.39 -0.13 (-1.04%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Myriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings GuidanceMyriad Genetics (NASDAQ:MYGN) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.140-0.150 for the period, compared to the consensus estimate of 0.130. The company also issued revenue guidance of $836.0 millionillion-$838.0 millionillion, compared to the consensus estimate of $840.2 millionillion.January 19 at 7:15 AM | marketbeat.comAnalysts Set Myriad Genetics, Inc. (NASDAQ:MYGN) Price Target at $24.27January 19 at 2:08 AM | americanbankingnews.comMyriad Genetics: Navigating Through A SetbackJanuary 16, 2025 | seekingalpha.comTD Cowen Sticks to Its Hold Rating for Myriad Genetics (MYGN)January 16, 2025 | markets.businessinsider.comMyriad Genetics: Sell Rating Maintained Amid Mixed Financial Outlook and Limited CatalystsJanuary 16, 2025 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Given "Equal Weight" Rating at StephensStephens reaffirmed an "equal weight" rating and issued a $20.00 target price on shares of Myriad Genetics in a research report on Thursday.January 16, 2025 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from AnalystsShares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have been given a consensus recommendation of "Hold" by the twelve analysts that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, six have issued a hold ratinJanuary 16, 2025 | marketbeat.comMyriad Genetics sees Q4 adjusted EPS 3c-4c, consensus 3cJanuary 15, 2025 | msn.comMyriad Genetics sees FY25 adjusted EPS 7c-11c, consensus 9cJanuary 15, 2025 | msn.comMyriad Genetics Reports Preliminary Q4 Results; Issues 2025 OutlookJanuary 15, 2025 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Hits New 12-Month Low - What's Next?Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month Low - Here's WhyJanuary 15, 2025 | marketbeat.comMyriad Genetics expects Q4 revenues to be between $209M and $211MJanuary 15, 2025 | seekingalpha.comMyriad Genetics (NASDAQ:MYGN) Releases Q4 2024 Earnings GuidanceMyriad Genetics (NASDAQ:MYGN) updated its fourth quarter 2024 earnings guidance. The company provided EPS guidance of 0.030-0.040 for the period, compared to the consensus estimate of 0.030. The company also issued revenue guidance of $209.0 millionillion-$211.0 millionillion, compared to the consensus estimate of $212.8 millionillion.January 15, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Updates FY 2025 Earnings GuidanceMyriad Genetics (NASDAQ:MYGN) updated its FY 2025 earnings guidance. The company provided EPS guidance of 0.070-0.110 for the period, compared to the consensus estimate of 0.090. The company also issued revenue guidance of $840.0 millionillion-$860.0 millionillion, compared to the consensus estimate of $883.1 millionillion.January 15, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Issues FY25 Earnings GuidanceMyriad Genetics (NASDAQ:MYGN) updated its FY25 earnings guidance. The company provided EPS guidance of $0.07-0.11 for the period, compared to the consensus estimate of $0.15. The company also issued revenue guidance of $840-860 millionillion, compared to the consensus estimate of $879.47 millionillion.January 15, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Issues Q4 Earnings GuidanceMyriad Genetics (NASDAQ:MYGN) updated its fourth quarter earnings guidance. The company provided EPS guidance of $0.03-0.04 for the period, compared to the consensus estimate of $0.03. The company also issued revenue guidance of $209-211 millionillion, compared to the consensus estimate of $212.87 millionillion.January 15, 2025 | marketbeat.comMyriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial GuidanceJanuary 15, 2025 | finance.yahoo.comMyriad Genetics (NASDAQ:MYGN) Stock Price Down 6% - Here's What HappenedMyriad Genetics (NASDAQ:MYGN) Trading Down 6% - What's Next?January 14, 2025 | marketbeat.comFY2024 EPS Estimates for Myriad Genetics Raised by AnalystJanuary 13, 2025 | americanbankingnews.comScotiabank Forecasts Higher Earnings for Myriad GeneticsMyriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Analysts at Scotiabank increased their FY2024 earnings per share (EPS) estimates for shares of Myriad Genetics in a research report issued on Wednesday, January 8th. Scotiabank analyst S. Nam now anticipates that the company will post earnings pJanuary 13, 2025 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Shares Bought by Nordea Investment Management ABNordea Investment Management AB increased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 117.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 332,913 shares of the company's stock after acquiring an additional 179,527 shares durJanuary 11, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Rating Increased to Buy at StockNews.comStockNews.com raised shares of Myriad Genetics from a "hold" rating to a "buy" rating in a report on Thursday.January 9, 2025 | marketbeat.comMyriad Genetics Partners with Hannah Storm to Promote Breast Cancer Risk AwarenessJanuary 9, 2025 | gurufocus.comMyriad Genetics Inc (MYGN) Partners with Hannah Storm to Promote Breast Cancer Risk AwarenessJanuary 9, 2025 | gurufocus.comMyriad Genetics Partners With Hannah Storm To Promote Breast Cancer Risk Assessment ProgramJanuary 9, 2025 | markets.businessinsider.comMyriad Genetics Partners with Hannah Storm to Promote Breast Cancer Risk Awareness Through Genetic TestingJanuary 9, 2025 | quiverquant.comMyriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer HistoryJanuary 9, 2025 | globenewswire.comUPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comMyriad Genetics Inc (MYGN) to Present at J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | gurufocus.comMyriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comMyriad Genetics, MD Anderson forms 5-year strategic allianceJanuary 7, 2025 | markets.businessinsider.comMD Anderson Enters 5-Year Deal With Myriad Genetics To Develop MRD AssayJanuary 7, 2025 | markets.businessinsider.comMyriad Genetics Inc (MYGN) Announces Strategic Alliance with MD Anderson Cancer CenterJanuary 7, 2025 | gurufocus.comMyriad Genetics Issues Quality, Innovation, and Corporate Responsibility ReportJanuary 6, 2025 | gurufocus.comMyriad Genetics Inc (MYGN) Releases Comprehensive Quality, Innovation, and Corporate ...January 6, 2025 | gurufocus.comMyriad Genetics Releases Quality, Innovation, and Corporate Responsibility Report for 2023-2024January 6, 2025 | quiverquant.comMyriad Genetics Issues Quality, Innovation, and Corporate Responsibility ReportJanuary 6, 2025 | globenewswire.comMyriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share PriceDecember 24, 2024 | finance.yahoo.comBarclays PLC Raises Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)Barclays PLC raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 136.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 190,243 shares of the company's stock after buying an addDecember 21, 2024 | marketbeat.comMyriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human GeneticsDecember 20, 2024 | markets.businessinsider.comMyriad Genetics Inc (MYGN) Unveils Study Highlighting RiskScore's Superior Accuracy in ...December 19, 2024 | gurufocus.comMyriad Genetics' MyRisk® Hereditary Cancer Test with RiskScore® Recognized as Top Advance in Genomic MedicineDecember 19, 2024 | quiverquant.comMyriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human GeneticsDecember 19, 2024 | globenewswire.comMyriad Genetics (NASDAQ:MYGN) Reaches New 52-Week Low - What's Next?Myriad Genetics (NASDAQ:MYGN) Reaches New 52-Week Low - Here's What HappenedDecember 18, 2024 | marketbeat.comState Street Corp Boosts Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)State Street Corp increased its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 8.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,703,442 shares of the company's stockDecember 15, 2024 | marketbeat.comMyriad Genetics price target lowered to $13 from $15 at BofADecember 13, 2024 | markets.businessinsider.comBank of America Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $13.00Bank of America decreased their target price on shares of Myriad Genetics from $15.00 to $13.00 and set an "underperform" rating on the stock in a report on Friday.December 13, 2024 | marketbeat.comUBS Initiates Coverage of Myriad Genetics (MYGN) with Neutral RecommendationDecember 11, 2024 | msn.comLeerink Partnrs Expects Lower Earnings for Myriad GeneticsMyriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Myriad Genetics in a research note issued to investors on Monday, December 9th. Leerink Partnrs analyst P. Souda now anticipates that the company will post eaDecember 11, 2024 | marketbeat.comMyriad Genetics Inc (MYGN) Expands Board with Appointment of Mark S. DavisDecember 10, 2024 | gurufocus.com Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address MYGN Media Mentions By Week MYGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYGN News Sentiment▼0.130.48▲Average Medical News Sentiment MYGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYGN Articles This Week▼256▲MYGN Articles Average Week Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FOLD News LGND News GERN News MNKD News DVAX News CLDX News BCRX News NVAX News INVA News OPK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYGN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYGN Stock Alerts